What is ARCT's health score?

Arcturus Therapeutics Holdings Inc. (ARCT) has a TradeApes health score of 31 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ARCT's estimated fair value?

Based on our 5-year discounted cash flow model, Arcturus Therapeutics Holdings Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ARCT undervalued or overvalued?

Our model currently rates ARCT as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

Create an account for unlimited access

Arcturus Therapeutics Holdings Inc. (ARCT)

Healthcare Inconclusive inconclusive weak

$6.77

Updated: 2026-07-14

TradeApes Score

Financial Strength

25 Stressed

Operating Trend

20 Stressed

Relative Value

30 Weak

Capital Allocation

30 Weak

Risk Management

80 Strong

Key Findings

+ Strong liquidity — current assets more than 2× current liabilities

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.